Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.56 |
| ▸ | BRD4 | O60885 | 5/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | STAT3 | P40763 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.42 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23015941 | 1.00 | CRBN (0.56) | CRBNBRD4HDAC1HDAC6HDAC3 | |
| SCHEMBL19068590 | 0.99 | CRBN (0.56) | CRBNBRD4HDAC1HDAC6HDAC3 | |
| SCHEMBL19387868 | 0.93 | CRBN (0.53) | CRBNBRD4HDAC1HDAC6HDAC3 | |
| SCHEMBL20013947 | 0.93 | CRBN (0.52) | CRBNBRD4HDAC1HDAC6HDAC3 | |
| SCHEMBL18492637 | 0.87 | CRBN (0.51) | CRBNBRD4HDAC1HDAC6HDAC3 | |
| SCHEMBL20153975 | 0.87 | CRBN (0.54) | CRBNBRD4HDAC1HDAC6HDAC3 | |
| SCHEMBL24937918 | 0.86 | STAT3 (0.51) | CRBNBRD4HDAC1HDAC6HDAC3 | |
| SCHEMBL20154048 | 0.85 | CRBN (0.52) | CRBNBRD4HDAC1HDAC6HDAC3 | |
| SCHEMBL19387899 | 0.84 | CRBN (0.54) | CRBNBRD4HDAC1HDAC6HDAC3 | |
| SCHEMBL24142023 | 0.83 | STAT3 (0.70) | CRBNBRD4HDAC1HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, XIAP, MDM2 | CRBN 1/4885BRD4 1005/4885HDAC1 2203/4885 |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885BRD4 687/4885HDAC1 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.